2-Alkylidene-18,19-Dinor-Vitamin D Compounds
First Claim
1. A compound having the formula:
- where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;
where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;
where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m-, —
(CH2)n-, or —
(CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.
0 Assignments
0 Petitions
Accused Products
Abstract
2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.
-
Citations
71 Claims
-
1. A compound having the formula:
-
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m-, —
(CH2)n-, or —
(CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17)
-
3. The compound of claim 1 where R is a side chain of the formula
-
4. The compound of claim 1 where R is a side chain of the formula
-
5. The compound of claim 1 where R is a side chain of the formula
-
6. The compound of claim 1 where R is a side chain of the formula
-
7. The compound of claim 1 where R is a side chain of the formula
-
8. The compound of claim 1 where R is a side chain of the formula
-
9. The compound of claim 1 where R is a side chain of the formula
-
10. The compound of claim 1 where R is a side chain of the formula
-
11. The compound of claim 1 where R is a side chain of the formula
-
13. A pharmaceutical composition containing an effective amount of at least one compound as claimed in claim 1 together with a pharmaceutically acceptable excipient.
-
14. The pharmaceutical composition of claim 13 wherein said effective amount comprises from about 0.01 μ
- g to about 100 μ
g per gram of composition.
- g to about 100 μ
-
15. The pharmaceutical composition of claim 13 wherein said effective amount comprises from about 0.1 μ
- g to about 50 μ
g per gram of composition.
- g to about 50 μ
-
16. The pharmaceutical composition of claim 13 containing (20S)-2-methylene-18,19-dinor-1α
- ,25-dihydroxyvitamin D3 in an amount from about 0.01 μ
g to about 100 μ
g.
- ,25-dihydroxyvitamin D3 in an amount from about 0.01 μ
-
17. The pharmaceutical composition of claim 13 containing (20S)-2-methylene-18,19-dinor-1α
- ,25-dihydroxyvitamin D3 in an amount from about 0.1 μ
g to about 50 μ
g.
- ,25-dihydroxyvitamin D3 in an amount from about 0.1 μ
-
-
12. (20S)-2-methylene-18,19-dinor-1α
- ,25-dihydroxyvitamin D3.
-
18. A compound having the formula:
-
19. A compound having the formula:
-
where X2 is —
H or a hydroxy protecting group.
-
-
20. A compound having the formula:
-
21. A compound having the formula:
-
where X3 is —
H or a hydroxy protecting group.
-
-
22. A method of treating metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of a compound having the formula:
-
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m—
, —
(CH2)n—
or —
(CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
34. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of a compound having the formula:
-
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m—
, —
(CH2)n—
or (CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (35, 36, 37, 38, 39, 40)
-
-
41. A method of treating leukemia, colon cancer, breast cancer, skin cancer or prostate cancer comprising administering to a patient an effective amount of a compound having the formula:
-
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m—
, —
(CH2)n—
or (CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (42, 43, 44, 45, 46)
-
-
47. A method of increasing the strength of a bone comprising administering to a patient in need of such treatment an effective amount of a compound having the formula:
-
where Y1 and Y2, which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group —
(CH2)x—
where X is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m—
, —
(CH2)n—
or (CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (48, 49, 50, 51, 52, 53, 54)
-
-
55. A method of treating an autoimmune disease comprising administering to a patient with said disease an effective amount of a compound having the formula
where Y1 and Y2 which may be the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group — - (CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m-, —
(CH2)n-, or —
(CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (56, 57, 58, 59, 60, 61, 62, 63)
- (CH2)x—
-
64. A method of treating an inflammatory bowel disease comprising administering to a patient with said disease an effective amount of a compound having the formula
where Y1 and Y2 which the same or different, are each selected from the group consisting of hydrogen and a hydroxy-protecting group, R6 and R8, which may be the same or different, are each selected from the group consisting of hydrogen, alkyl, hydroxyalkyl and fluoroalkyl, or, when taken together represent the group — - (CH2)x—
where x is an integer from 2 to 5, and where the group R is represented by the structure;where the stereochemical center at carbon 20 may have the R or S configuration, and where Z is selected from Y, —
OY, —
CH2OY, —
C≡
CY and —
CH═
CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, —
COR5 and a radical of the structure;where m and n, independently, represent the integers from 0 to 5, where R1 is selected from hydrogen, deuterium, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C1-5-alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R2, R3, and R4, independently, is selected from deuterium, deuteroalkyl, hydrogen, fluoro, trifluoromethyl and C1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R1 and R2, taken together, represent an oxo group, or an alkylidene group, ═
CR2R3, or the group —
(CH2)p—
, where p is an integer from 2 to 5, and where R3 and R4, taken together, represent an oxo group, or the group —
(CH2)q—
, where q is an integer from 2 to 5, and where R5 represents hydrogen, hydroxy, protected hydroxy, or C1-5 alkyl and wherein any of the CH-groups at positions 20, 22, or 23 in the side chain may be replaced by a nitrogen atom, or where any of the groups —
CH(CH3)—
, —
(CH2)m-, —
(CH2)n-, or —
(CR1R2)—
at positions 20, 22, and 23, respectively, may be replaced by an oxygen or sulfur atom.- View Dependent Claims (65, 66, 67, 68, 69, 70, 71)
- (CH2)x—
Specification